Afatinib in Advanced Refractory Urothelial Cancer

Summary

This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.

Timeline

Start

2017-09-13

Primary completion

2024-04-04

Completion

2024-04-04

Drugs

Indications